Llwytho...
Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other second‐ and third‐line antidiabetic drugs in patients with type 2 diabetes
AIMS: Dipeptidyl peptidase 4 inhibitors (DPP4is) are suggested as a second‐ and third‐line antidiabetic treatment for type 2 diabetes. Previous studies assessed only the cardiovascular effects of DPP4is as a second‐line treatment, included sulphonylurea as the only comparator, and yielded inconclusi...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Br J Clin Pharmacol |
|---|---|
| Prif Awduron: | , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
John Wiley and Sons Inc.
2017
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5465327/ https://ncbi.nlm.nih.gov/pubmed/28109184 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13241 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|